Skip to content
Back to outputs

BRAF V600 co-testing is technically feasible in conventional thyroid fine needle aspiration (FNA) cytology smears and can reduce the need for completion thyroidectomy

Research output: Contribution to journalArticlepeer-review

Standard

BRAF V600 co-testing is technically feasible in conventional thyroid fine needle aspiration (FNA) cytology smears and can reduce the need for completion thyroidectomy. / Poller, D. N.; Glaysher, S.

In: Cancer Cytopathology, Vol. 25, No. 3, 20.05.2014, p. 155-9.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{dd5d40ebf1744badbfd60cd0b137b6f1,
title = "BRAF V600 co-testing is technically feasible in conventional thyroid fine needle aspiration (FNA) cytology smears and can reduce the need for completion thyroidectomy",
abstract = "Introduction: While fine needle aspiration cytology (FNAC) is the mainstay of diagnosis in thyroid nodules, molecular markers of thyroid cancer have recently been shown to be of value in improving the diagnosis and reducing the rates of unnecessary surgery.Method: A technical method is presented for the assessment of the BRAF V600 gene mutation in thyroid cancer using a simple adaptation of a commercially available kit. After standard preparation and reporting of conventionally stained alcohol-fixed Papanicolaou or air-dried Giemsa-stained slides the coverslip is removed from one slide, the DNA is extracted and submitted for PCR analysis.Results: Assessment of the BRAF V600 mutational status is feasible in very small quantities of DNA, requiring just greater than 5 ng per case from a single pre-stained FNA slide using this method. From the 14 cases examined thus far, one Thy4/Bethesda Class V case (suspicious of malignancy) has been identified with a BRAF V600 mutation and this patient, after multidisciplinary discussion, received a total thyroidectomy.Conclusion: Based on this methodology and other published results for the BRAF mutation, we believe that it is now feasible and cost effective for the UK NHS to BRAF co-test all Thy4/Bethesda Class V thyroid FNAs, as the additional cost of BRAF testing will still be much less than the cost of submitting all Thy4 (Bethesda Class V) patients to a partial and then a later completion thyroidectomy.",
keywords = "biopsy, fine-needle, cytodiagnosis, DNA mutational analysis, humans, proto-oncogene proteins B-raf, thyroid gland, thyroid neoplasms, thyroid nodule, thyroidectomy, BRAF, research support, non-U.S. Gov't, diagnosis, papillary thyroid cancer, FNA, fine needle aspiration",
author = "Poller, {D. N.} and S. Glaysher",
note = "{\textcopyright} 2013 John Wiley & Sons Ltd.",
year = "2014",
month = may,
day = "20",
doi = "10.1111/cyt.12109",
language = "English",
volume = "25",
pages = "155--9",
journal = "Cancer Cytopathology",
issn = "1934-662X",
publisher = "Wiley",
number = "3",

}

RIS

TY - JOUR

T1 - BRAF V600 co-testing is technically feasible in conventional thyroid fine needle aspiration (FNA) cytology smears and can reduce the need for completion thyroidectomy

AU - Poller, D. N.

AU - Glaysher, S.

N1 - © 2013 John Wiley & Sons Ltd.

PY - 2014/5/20

Y1 - 2014/5/20

N2 - Introduction: While fine needle aspiration cytology (FNAC) is the mainstay of diagnosis in thyroid nodules, molecular markers of thyroid cancer have recently been shown to be of value in improving the diagnosis and reducing the rates of unnecessary surgery.Method: A technical method is presented for the assessment of the BRAF V600 gene mutation in thyroid cancer using a simple adaptation of a commercially available kit. After standard preparation and reporting of conventionally stained alcohol-fixed Papanicolaou or air-dried Giemsa-stained slides the coverslip is removed from one slide, the DNA is extracted and submitted for PCR analysis.Results: Assessment of the BRAF V600 mutational status is feasible in very small quantities of DNA, requiring just greater than 5 ng per case from a single pre-stained FNA slide using this method. From the 14 cases examined thus far, one Thy4/Bethesda Class V case (suspicious of malignancy) has been identified with a BRAF V600 mutation and this patient, after multidisciplinary discussion, received a total thyroidectomy.Conclusion: Based on this methodology and other published results for the BRAF mutation, we believe that it is now feasible and cost effective for the UK NHS to BRAF co-test all Thy4/Bethesda Class V thyroid FNAs, as the additional cost of BRAF testing will still be much less than the cost of submitting all Thy4 (Bethesda Class V) patients to a partial and then a later completion thyroidectomy.

AB - Introduction: While fine needle aspiration cytology (FNAC) is the mainstay of diagnosis in thyroid nodules, molecular markers of thyroid cancer have recently been shown to be of value in improving the diagnosis and reducing the rates of unnecessary surgery.Method: A technical method is presented for the assessment of the BRAF V600 gene mutation in thyroid cancer using a simple adaptation of a commercially available kit. After standard preparation and reporting of conventionally stained alcohol-fixed Papanicolaou or air-dried Giemsa-stained slides the coverslip is removed from one slide, the DNA is extracted and submitted for PCR analysis.Results: Assessment of the BRAF V600 mutational status is feasible in very small quantities of DNA, requiring just greater than 5 ng per case from a single pre-stained FNA slide using this method. From the 14 cases examined thus far, one Thy4/Bethesda Class V case (suspicious of malignancy) has been identified with a BRAF V600 mutation and this patient, after multidisciplinary discussion, received a total thyroidectomy.Conclusion: Based on this methodology and other published results for the BRAF mutation, we believe that it is now feasible and cost effective for the UK NHS to BRAF co-test all Thy4/Bethesda Class V thyroid FNAs, as the additional cost of BRAF testing will still be much less than the cost of submitting all Thy4 (Bethesda Class V) patients to a partial and then a later completion thyroidectomy.

KW - biopsy, fine-needle

KW - cytodiagnosis

KW - DNA mutational analysis

KW - humans

KW - proto-oncogene proteins B-raf

KW - thyroid gland

KW - thyroid neoplasms

KW - thyroid nodule

KW - thyroidectomy

KW - BRAF

KW - research support, non-U.S. Gov't

KW - diagnosis

KW - papillary thyroid cancer

KW - FNA

KW - fine needle aspiration

U2 - 10.1111/cyt.12109

DO - 10.1111/cyt.12109

M3 - Article

C2 - 24164374

VL - 25

SP - 155

EP - 159

JO - Cancer Cytopathology

JF - Cancer Cytopathology

SN - 1934-662X

IS - 3

ER -

ID: 4757443